Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Phio Pharmaceuticals Corp
(NQ:
PHIO
)
2.680
+0.130 (+5.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Phio Pharmaceuticals Corp
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
October 07, 2024
INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp....
Via
Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
October 02, 2024
Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2,...
Via
Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
October 01, 2024
Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
September 25, 2024
Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
September 17, 2024
Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - September 17,...
Via
Newsfile
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
September 16, 2024
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September...
Via
Newsfile
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 09, 2024
Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp....
Via
Newsfile
Topics
Intellectual Property
Exposures
Intellectual Property
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
August 29, 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
August 06, 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Topics
Intellectual Property
Exposures
Intellectual Property
Phio Pharmaceuticals Announces New Chief Financial Officer
August 01, 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Topics
Initial Public Offering
Exposures
Securities Market
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
July 12, 2024
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company...
Via
Newsfile
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
July 08, 2024
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8,...
Via
Newsfile
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
July 05, 2024
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Phio Pharmaceuticals Announces Reverse Stock Split
July 02, 2024
Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company...
Via
Newsfile
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
June 18, 2024
Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) -...
Via
Newsfile
Topics
Intellectual Property
Exposures
Intellectual Property
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
May 28, 2024
Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May...
Via
Newsfile
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 23, 2024
Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
May 09, 2024
From
Phio Pharmaceuticals Corp.
Via
GlobeNewswire
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
April 02, 2024
From
Phio Pharmaceuticals Corp.
Via
GlobeNewswire
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Phio Pharmaceuticals Corp.
Via
GlobeNewswire
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Phio Pharmaceuticals Corp.
Via
GlobeNewswire
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) Near the Top of Equities by Percentage Gain on 4/18
April 18, 2023
Via
Investor Brand Network
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
September 17, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.